Skip to content

Comparison of Histology From a Mesh Sponge and Traditional Esophageal Biopsies in Children and Adolescents With EoE

Comparison of Histological Results Obtained From a Mesh Sponge (CytospongeTM) and Traditional Esophageal Mucosal Biopsies in Children and Adolescents With Eosinophilic Esophagitis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05342168
Enrollment
30
Registered
2022-04-22
Start date
2022-04-01
Completion date
2023-09-01
Last updated
2022-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic Esophagitis

Keywords

cytosponge, esophageal biopsy, Histology

Brief summary

The aim of the present study is determining the accuracy, safety and tolerance of the CytospongeTM (expandable sponge within a gelatin capsule attached to a string) relative to traditional upper endoscopy and esophageal biopsies in older children and adolescents with a diagnosis of Eosinophilic Esophagitis (EoE) to follow up on treatment changes. The findings from this study could help determine whether the CytospongeTM is a more cost-effective alternative to traditional upper endoscopy for histologic follow-up in children and adolescents with EoE.

Detailed description

This is a cross-sectional study in pediatric subjects comparing histologic findings on esophageal biopsies obtained during upper GI endoscopies to histologic findings on tissue samples obtained through the use of the CytospongeTM in a group of paediatric patients with a diagnosis of EoE. Subjects will swallow the Cytosponge capsule (attached to a string) several hours prior to their scheduled endoscopy for treatment assessment. An esophageal sample will be obtained by withdrawing the expanded sponge thru the esophagus. This will be sent to pathology and fixed and stained. The subject will also undergo routine upper endoscopy under conscious sedation and follow up biopsies obtained as per routine standard of care to assess current treatment for EoE. There will be a blinded comparison between the biopsies and the Cytosponge sample by two pediatric pathologist with experience with EoE. Subjects and their caregivers will also be surveyed on their experience using the Cytosponge compared to having endoscopy. This study has been performed in adults with Eosinophilic Esophagitis and found that the samples obtained with the Cytosponge was equivalent to the endoscopically obtained biopspes with out having to use endoscopy. Adult subjects also preferred the Sponge over having an endoscopy. The Cytosponge was shown to be safe and effected. Even larger adult trials in screening for esophageal cancer have shown the Cytosponge is safe and effective at sampling the esophagus.

Interventions

DIAGNOSTIC_TESTUsing a swallowed expanding sponge (Cytosponge TM) to obtain sampling of the esophageal musosa

A gelatin capsule containing the collapsed mesh sponge is swallowed with an attached string fixed to the cheek. After 8 minutes the gelatin capsule will have dissolved and the expanded soft mesh sponge can be with drawn sampling the surface of the esophagus on the way out. The sponge then will be spun and the supernant fixed, processed and stained.

Sponsors

The Hospital for Sick Children
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

Each sample type is read by a pathologist blinded to the traditional ly obtained biopsy

Intervention model description

cross sectional study comparing to tissue sampling methods

Eligibility

Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Previous histologic diagnosis of eosinophilic esophagitis (symptoms of esophageal dysfunction and at least 15 eosinophils per high-power field on esophageal biopsy and after a comprehensive assessment of non-EoE disorders that could cause or potentially contribute to esophageal eosinophilia).1 * Capable of swallowing a capsule 3 cm in length (trial with 3 cm jelly candy). * 10 to 18 years of age. * Male or female. * Able to give assent or consent. * Scheduled for an upper gastrointestinal endoscopy with biopsies on the same day to assess response to therapy and make decisions regarding further management.

Exclusion criteria

* Unable to swallow the capsule. * Unable to give assent or consent. * History of esophageal stricture on either upper gastrointestinal barium study or previous upper gastrointestinal endoscopy of food impaction that required removal. * History of portal hypertension or esophageal varices. * History of solid organ transplantation. * Known bleeding diathesis. * On anticoagulation therapy. * Known platelet count less than normal for age. * Pregnancy. * Need for intubation during endoscopy. * History of previous esophageal surgery.

Design outcomes

Primary

MeasureTime frameDescription
Eosinophil count per high power field obtained from Cytosponge supernant and endoscopic esophageal biopsies will be compared1 weekComparison of histology by counting the number of eosinophilis seen per high power field results from supernatant sample obtained via mesh sponge withdrawal thru the esophagus to samples obtained by the gold standard traditional esophageal biopsy.

Secondary

MeasureTime frameDescription
Likert scale (10 point) evaluating patient and caregiver satisfactionimmediately following the endoscopy procedureBoth patient and caregiver satisfaction will be assessed comparing the sponge method verses tradition upper will endoscopy with biopsy using a 10 point likert scale (1 to 10) with 10 being the better outcome.
Questionairre evaluating Patient and caregiver satisfactionimmediately following endoscopy procedureBoth patient and caregiver satisfaction will be assessed comparing the sponge method verses tradition upper will endoscopy with biopsy using a satisfaction questionnaire.
Histology comparison of supernant obtained from sponge and esophageal pinch biopsesone weekSupernant samples and esophageal biopsies will be fixed and stained and then reviewed by the study pathologist to compare findings

Countries

Canada

Contacts

Primary ContactKristen Bortolin, MD
kristen.bortolin@sickkids.ca4168137735
Backup ContactMargaret Marcon, MD
peggy.marcon@sickkids.ca4168137735

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026